Responsiveness and minimal important difference of the urticaria control test

J Allergy Clin Immunol. 2017 Dec;140(6):1710-1713.e11. doi: 10.1016/j.jaci.2017.04.050. Epub 2017 Jun 16.

Affiliations

¹ Department of Dermatology and Allergy, Allergie-Centrum-Charité, Charité-Universitätsmedizin Berlin, Berlin, Germany.
² Department of Dermatology, University Medical Center Mainz, Mainz, Germany.
³ Department of Dermatology and Allergy, Allergie-Centrum-Charité, Charité-Universitätsmedizin Berlin, Berlin, Germany. Electronic address: karsten.weller@charite.de.

PMID: 28625805
DOI: 10.1016/j.jaci.2017.04.050

No abstract available

Publication types

Clinical Trial
Letter

MeSH terms

Adult
Anti-Allergic Agents / therapeutic use*
Chronic Disease
Female
Humans
Male
Middle Aged
Omalizumab / therapeutic use*
Quality of Life*
Severity of Illness Index*
Treatment Outcome
Urticaria / drug therapy*

Substances

Anti-Allergic Agents
Omalizumab